238 related articles for article (PubMed ID: 11302795)
21. In vitro susceptibility of Cryptococcus gattii clinical isolates.
Gomez-Lopez A; Zaragoza O; Dos Anjos Martins M; Melhem MC; Rodriguez-Tudela JL; Cuenca-Estrella M
Clin Microbiol Infect; 2008 Jul; 14(7):727-30. PubMed ID: 18558948
[TBL] [Abstract][Full Text] [Related]
22. Combined activity of amphotericin B and 5-fluorocytosine against Cryptococcus neoformans in vitro and in vivo in mice.
Hamilton JD; Elliott DM
J Infect Dis; 1975 Feb; 131(2):129-37. PubMed ID: 1090685
[TBL] [Abstract][Full Text] [Related]
23. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004).
Pfaller MA; Messer SA; Boyken L; Rice C; Tendolkar S; Hollis RJ; Doern GV; Diekema DJ
J Clin Microbiol; 2005 May; 43(5):2163-7. PubMed ID: 15872236
[TBL] [Abstract][Full Text] [Related]
24. The combination of tamoxifen with amphotericin B, but not with fluconazole, has synergistic activity against the majority of clinical isolates of Cryptococcus neoformans.
Hai TP; Van AD; Ngan NTT; Nhat LTH; Lan NPH; Vinh Chau NV; Thwaites GE; Krysan D; Day JN
Mycoses; 2019 Sep; 62(9):818-825. PubMed ID: 31173410
[TBL] [Abstract][Full Text] [Related]
25. In vitro susceptibility of Cryptococcus neoformans clinical isolates from Egypt to seven antifungal drugs.
Abdel-Salam HA
Mycoses; 2005 Sep; 48(5):327-32. PubMed ID: 16115103
[TBL] [Abstract][Full Text] [Related]
26. In vitro activities of voriconazole in combination with three other antifungal agents against Candida glabrata.
Barchiesi F; Spreghini E; Maracci M; Fothergill AW; Baldassarri I; Rinaldi MG; Scalise G
Antimicrob Agents Chemother; 2004 Sep; 48(9):3317-22. PubMed ID: 15328091
[TBL] [Abstract][Full Text] [Related]
27. In vitro and in vivo studies on synergistic antifungal activity.
Shadomy S
Contrib Microbiol Immunol; 1977; 4():147-57. PubMed ID: 342191
[No Abstract] [Full Text] [Related]
28. Effects of several antifungal drug combinations against clinical and environmental isolates of Cryptococcus neoformans from China.
Zhu LP; Gil-Lamaignere C; Müller FM
Mycoses; 2004 Aug; 47(7):319-25. PubMed ID: 15310338
[TBL] [Abstract][Full Text] [Related]
29. Amphotericin B and fluconazole, a potent combination therapy for cryptococcal meningitis.
Larsen RA; Bauer M; Thomas AM; Graybill JR
Antimicrob Agents Chemother; 2004 Mar; 48(3):985-91. PubMed ID: 14982793
[TBL] [Abstract][Full Text] [Related]
30. Astemizole and an analogue promote fungicidal activity of fluconazole against Cryptococcus neoformans var. grubii and Cryptococcus gattii.
Vu K; Gelli A
Med Mycol; 2010 Mar; 48(2):255-62. PubMed ID: 19572230
[TBL] [Abstract][Full Text] [Related]
31. Activity of sertraline against Cryptococcus neoformans: in vitro and in vivo assays.
Treviño-Rangel Rde J; Villanueva-Lozano H; Hernández-Rodríguez P; Martínez-Reséndez MF; García-Juárez J; Rodríguez-Rocha H; González GM
Med Mycol; 2016 Mar; 54(3):280-6. PubMed ID: 26705833
[TBL] [Abstract][Full Text] [Related]
32. In vitro antifungal susceptibility profiles of Cryptococcus species isolated from HIV-associated cryptococcal meningitis patients in Zimbabwe.
Nyazika TK; Herkert PF; Hagen F; Mateveke K; Robertson VJ; Meis JF
Diagn Microbiol Infect Dis; 2016 Nov; 86(3):289-292. PubMed ID: 27608538
[TBL] [Abstract][Full Text] [Related]
33. Synergistic effect of the verapamil and amphotericin B against Cryptococcus neoformans.
Pereira TC; do Carmo PHF; de Menezes RT; de Oliveira HC; de Oliveira LD; Junqueira JC; Scorzoni L
Folia Microbiol (Praha); 2023 Dec; 68(6):999-1004. PubMed ID: 37950840
[TBL] [Abstract][Full Text] [Related]
34. Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998.
Brandt ME; Pfaller MA; Hajjeh RA; Hamill RJ; Pappas PG; Reingold AL; Rimland D; Warnock DW;
Antimicrob Agents Chemother; 2001 Nov; 45(11):3065-9. PubMed ID: 11600357
[TBL] [Abstract][Full Text] [Related]
35. In vitro activity of the synthetic lipopeptide PAL-Lys-Lys-NH(2) alone and in combination with antifungal agents against clinical isolates of Cryptococcus neoformans.
Barchiesi F; Giacometti A; Cirioni O; Arzeni D; Silvestri C; Kamysz W; Abbruzzetti A; Riva A; Kamysz E; Scalise G
Peptides; 2007 Aug; 28(8):1509-13. PubMed ID: 17698253
[TBL] [Abstract][Full Text] [Related]
36. Serotypes of clinical cerebrospinal fluid Cryptococcus neoformans isolates from southern Taiwan and their in vitro susceptibilities to amphotericin B, fluconazole, and voriconazole.
Chang WN; Huang CR; Lei CB; Lee PY; Chien CC; Chang HW; Chang CS; Lu CH
Jpn J Infect Dis; 2004 Jun; 57(3):113-5. PubMed ID: 15218221
[TBL] [Abstract][Full Text] [Related]
37. Effects of fluconazole singly and in combination with 5-fluorocytosine or amphotericin B in the treatment of cryptococcal meningoencephalitis in an intracranial murine model.
Hossain MA; Mukherjee PK; Reyes G; Long L; Ghannoum MA
J Chemother; 2002 Aug; 14(4):351-60. PubMed ID: 12420852
[TBL] [Abstract][Full Text] [Related]
38. Current approach to the acute management of cryptococcal infections.
Powderly WG
J Infect; 2000 Jul; 41(1):18-22. PubMed ID: 11041709
[No Abstract] [Full Text] [Related]
39. Fluconazole and amphotericin B susceptibility testing of Cryptococcus neoformans: results of minimal inhibitory concentrations against 265 isolates from HIV-positive patients before and after two or more months of antifungal therapy.
Arechavala AI; Ochiuzzi ME; Borgnia MD; Santiso GM
Rev Iberoam Micol; 2009 Sep; 26(3):194-7. PubMed ID: 19635445
[TBL] [Abstract][Full Text] [Related]
40. Susceptibility of clinical isolates of Cryptococcus neoformans to amphotericin B using time-kill methodology.
Pappalardo MC; Szeszs MW; Martins MA; Baceti LB; Bonfietti LX; Purisco SU; Baez AA; Melhem MS
Diagn Microbiol Infect Dis; 2009 Jun; 64(2):146-51. PubMed ID: 19345042
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
